Truist Financial Boosts Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $17.00

Amneal Pharmaceuticals (NASDAQ:AMRX) had its target price upped by equities research analysts at Truist Financial from $15.00 to $17.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s target price suggests a potential upside of 23.10% from the company’s previous close.

A number of other research analysts also recently issued reports on AMRX. Barclays began coverage on shares of Amneal Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $15.00 price target for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Amneal Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $14.20.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX opened at $13.81 on Monday. Amneal Pharmaceuticals has a 1 year low of $6.68 and a 1 year high of $15.42. The stock has a market capitalization of $4.34 billion, a PE ratio of 60.05 and a beta of 1.36. The stock has a 50-day simple moving average of $13.74 and a 200-day simple moving average of $11.76.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of AMRX. Kemnay Advisory Services Inc. purchased a new stake in Amneal Pharmaceuticals in the fourth quarter valued at $26,000. Federated Hermes Inc. increased its position in shares of Amneal Pharmaceuticals by 1,680.6% during the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares in the last quarter. Spire Wealth Management lifted its holdings in shares of Amneal Pharmaceuticals by 66.6% in the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after purchasing an additional 1,023 shares during the last quarter. Transamerica Financial Advisors LLC boosted its position in shares of Amneal Pharmaceuticals by 541.9% in the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after purchasing an additional 2,460 shares during the period. Finally, Comerica Bank grew its stake in Amneal Pharmaceuticals by 186.7% during the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after buying an additional 1,957 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.